Recombinant Human TMIGD2 Protein，His

TMIGD2, or Transmembrane and Immunoglobulin Domain Containing 2, is a protein that has garnered increasing interest in the field of immunology and cancer research. Discovered as a novel immunoglobulin-like receptor, TMIGD2 is primarily expressed in immune cells and plays a vital role in regulating immune responses. Its significance stems from its potential involvement in modulating T cell activation and survival, as well as its correlation with various diseases, including autoimmune disorders and cancers. The study of recombinant TMIGD2 protein is crucial for understanding its functional mechanisms and interactions with other proteins, as well as its potential as a therapeutic target. Researchers aim to characterize the structural and functional properties of TMIGD2 through recombinant expression systems, enabling them to explore its signaling pathways and biological implications. Furthermore, elucidating the role of TMIGD2 in tumor microenvironments may provide insights into immune evasion strategies employed by cancer cells, thereby contributing to the development of novel immunotherapies. With ongoing research on TMIGD2 and its implications in immune regulation, the recombinant protein serves as a pivotal tool for unraveling the complex networks of cellular communication within the immune system and offers promising avenues for therapeutic intervention in immune-related diseases.